ZA200307682B - Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist. - Google Patents

Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist. Download PDF

Info

Publication number: ZA200307682B
Authority: ZA; South Africa
Prior art keywords: vegf; vegfr; antibody; substance; composition
Prior art date: 2001-03-02

Application number

ZA200307682A

Other languages

English (en)

Inventor

Patricia Rockwell

Neil I Goldstein

Original Assignee

Imclone Systems Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-02

Filing date

2003-10-01

Publication date

2005-01-13

2003-10-01 Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc

2005-01-13 Publication of ZA200307682B publication Critical patent/ZA200307682B/en

Links

108091008605 VEGF receptors Proteins 0.000 title claims description 180
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims description 163
238000000034 method Methods 0.000 title claims description 110
239000002464 receptor antagonist Substances 0.000 title claims description 53
230000004614 tumor growth Effects 0.000 title claims description 44
230000002401 inhibitory effect Effects 0.000 title claims description 35
229940124676 vascular endothelial growth factor receptor Drugs 0.000 title description 65
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 208
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 208
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 208
102000005962 receptors Human genes 0.000 claims description 168
108020003175 receptors Proteins 0.000 claims description 168
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 153
206010028980 Neoplasm Diseases 0.000 claims description 110
230000027455 binding Effects 0.000 claims description 98
102000001301 EGF receptor Human genes 0.000 claims description 94
108060006698 EGF receptor Proteins 0.000 claims description 92
239000005557 antagonist Substances 0.000 claims description 76
239000000203 mixture Substances 0.000 claims description 58
239000000126 substance Substances 0.000 claims description 55
238000011282 treatment Methods 0.000 claims description 54
229940044551 receptor antagonist Drugs 0.000 claims description 52
239000003446 ligand Substances 0.000 claims description 51
229940122558 EGFR antagonist Drugs 0.000 claims description 43
239000002246 antineoplastic agent Substances 0.000 claims description 42
150000003384 small molecules Chemical class 0.000 claims description 36
230000005855 radiation Effects 0.000 claims description 35
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 31
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims description 30
229940127089 cytotoxic agent Drugs 0.000 claims description 30
230000012010 growth Effects 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 17
229940123777 Vascular endothelial growth factor (VEGF)receptor antagonist Drugs 0.000 claims description 13
229940034982 antineoplastic agent Drugs 0.000 claims description 13
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 7
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
229930012538 Paclitaxel Natural products 0.000 claims description 6
210000004185 liver Anatomy 0.000 claims description 6
229960001592 paclitaxel Drugs 0.000 claims description 6
210000003491 skin Anatomy 0.000 claims description 6
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 5
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 5
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 5
210000004556 brain Anatomy 0.000 claims description 5
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
229960004316 cisplatin Drugs 0.000 claims description 5
210000003734 kidney Anatomy 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
210000002307 prostate Anatomy 0.000 claims description 5
210000000952 spleen Anatomy 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
229960004679 doxorubicin Drugs 0.000 claims description 4
210000003128 head Anatomy 0.000 claims description 4
210000002216 heart Anatomy 0.000 claims description 4
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 4
210000003739 neck Anatomy 0.000 claims description 4
210000001672 ovary Anatomy 0.000 claims description 4
229960003171 plicamycin Drugs 0.000 claims description 4
210000000813 small intestine Anatomy 0.000 claims description 4
229960001052 streptozocin Drugs 0.000 claims description 4
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
210000001541 thymus gland Anatomy 0.000 claims description 4
210000003932 urinary bladder Anatomy 0.000 claims description 4
210000004291 uterus Anatomy 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 3
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 3
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 3
210000004369 blood Anatomy 0.000 claims description 3
239000008280 blood Substances 0.000 claims description 3
210000000988 bone and bone Anatomy 0.000 claims description 3
210000001185 bone marrow Anatomy 0.000 claims description 3
210000003679 cervix uteri Anatomy 0.000 claims description 3
229960003901 dacarbazine Drugs 0.000 claims description 3
229960004961 mechlorethamine Drugs 0.000 claims description 3
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 3
210000000496 pancreas Anatomy 0.000 claims description 3
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 claims description 2
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
108010024976 Asparaginase Proteins 0.000 claims description 2
102000015790 Asparaginase Human genes 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
108010092160 Dactinomycin Proteins 0.000 claims description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
102000006992 Interferon-alpha Human genes 0.000 claims description 2
108010047761 Interferon-alpha Proteins 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
108010000817 Leuprolide Proteins 0.000 claims description 2
229930192392 Mitomycin Natural products 0.000 claims description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
229960005310 aldesleukin Drugs 0.000 claims description 2
108700025316 aldesleukin Proteins 0.000 claims description 2
229960003272 asparaginase Drugs 0.000 claims description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
229960002092 busulfan Drugs 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
229960005243 carmustine Drugs 0.000 claims description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
229960004630 chlorambucil Drugs 0.000 claims description 2
229960002436 cladribine Drugs 0.000 claims description 2
229960004397 cyclophosphamide Drugs 0.000 claims description 2
229960000684 cytarabine Drugs 0.000 claims description 2
229960000640 dactinomycin Drugs 0.000 claims description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
229960000975 daunorubicin Drugs 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
229960000961 floxuridine Drugs 0.000 claims description 2
229960000390 fludarabine Drugs 0.000 claims description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
229960001101 ifosfamide Drugs 0.000 claims description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
229960004338 leuprorelin Drugs 0.000 claims description 2
229960002247 lomustine Drugs 0.000 claims description 2
229960001786 megestrol Drugs 0.000 claims description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
229960001924 melphalan Drugs 0.000 claims description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
229960001428 mercaptopurine Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
229960004857 mitomycin Drugs 0.000 claims description 2
229960000350 mitotane Drugs 0.000 claims description 2
229960001744 pegaspargase Drugs 0.000 claims description 2
108010001564 pegaspargase Proteins 0.000 claims description 2
229960002340 pentostatin Drugs 0.000 claims description 2
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims description 2
229960000952 pipobroman Drugs 0.000 claims description 2
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
229960000624 procarbazine Drugs 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
229960001278 teniposide Drugs 0.000 claims description 2
210000001550 testis Anatomy 0.000 claims description 2
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 2
229960005353 testolactone Drugs 0.000 claims description 2
229960001196 thiotepa Drugs 0.000 claims description 2
229960003087 tioguanine Drugs 0.000 claims description 2
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
229960001055 uracil mustard Drugs 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
229960002066 vinorelbine Drugs 0.000 claims description 2
230000001419 dependent effect Effects 0.000 claims 20
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
190000008236 carboplatin Chemical compound 0.000 claims 1
229960003668 docetaxel Drugs 0.000 claims 1
210000004027 cell Anatomy 0.000 description 250
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 230
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 95
108090000623 proteins and genes Proteins 0.000 description 72
230000004913 activation Effects 0.000 description 49
102000004169 proteins and genes Human genes 0.000 description 49
238000003556 assay Methods 0.000 description 48
230000005764 inhibitory process Effects 0.000 description 45
108020004414 DNA Proteins 0.000 description 44
230000000694 effects Effects 0.000 description 41
230000026731 phosphorylation Effects 0.000 description 39
210000002889 endothelial cell Anatomy 0.000 description 38
238000006366 phosphorylation reaction Methods 0.000 description 38
230000014509 gene expression Effects 0.000 description 37
239000013598 vector Substances 0.000 description 37
241000700159 Rattus Species 0.000 description 36
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 34
239000002953 phosphate buffered saline Substances 0.000 description 34
239000002609 medium Substances 0.000 description 32
210000004881 tumor cell Anatomy 0.000 description 28
241000699666 Mus <mouse, genus> Species 0.000 description 27
230000033115 angiogenesis Effects 0.000 description 27
241000699670 Mus sp. Species 0.000 description 26
150000001413 amino acids Chemical group 0.000 description 26
208000005017 glioblastoma Diseases 0.000 description 26
210000004408 hybridoma Anatomy 0.000 description 26
230000003993 interaction Effects 0.000 description 25
230000000903 blocking effect Effects 0.000 description 24
241000124008 Mammalia Species 0.000 description 23
241001465754 Metazoa Species 0.000 description 22
238000002965 ELISA Methods 0.000 description 21
150000001875 compounds Chemical class 0.000 description 21
108090000765 processed proteins & peptides Proteins 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
239000012634 fragment Substances 0.000 description 20
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical group 0.000 description 19
238000004458 analytical method Methods 0.000 description 18
238000001514 detection method Methods 0.000 description 18
102000002260 Alkaline Phosphatase Human genes 0.000 description 17
108020004774 Alkaline Phosphatase Proteins 0.000 description 17
-1 5: 519-524 (1990) Proteins 0.000 description 16
241001529936 Murinae Species 0.000 description 16
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 16
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
238000001114 immunoprecipitation Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
238000002347 injection Methods 0.000 description 16
238000001262 western blot Methods 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
241000283973 Oryctolagus cuniculus Species 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
238000011534 incubation Methods 0.000 description 15
230000000638 stimulation Effects 0.000 description 15
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 15
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 14
239000013615 primer Substances 0.000 description 14
102400001368 Epidermal growth factor Human genes 0.000 description 13
101800003838 Epidermal growth factor Proteins 0.000 description 13
201000011510 cancer Diseases 0.000 description 13
229940116977 epidermal growth factor Drugs 0.000 description 13
238000003566 phosphorylation assay Methods 0.000 description 13
239000013612 plasmid Substances 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
241000283707 Capra Species 0.000 description 12
241000588724 Escherichia coli Species 0.000 description 12
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 12
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 12
240000004808 Saccharomyces cerevisiae Species 0.000 description 12
238000001042 affinity chromatography Methods 0.000 description 12
239000011324 bead Substances 0.000 description 12
239000002299 complementary DNA Substances 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 11
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 11
239000000872 buffer Substances 0.000 description 11
239000013604 expression vector Substances 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
206010003445 Ascites Diseases 0.000 description 10
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 10
239000013592 cell lysate Substances 0.000 description 10
230000002860 competitive effect Effects 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000006386 neutralization reaction Methods 0.000 description 10
238000003752 polymerase chain reaction Methods 0.000 description 10
230000009467 reduction Effects 0.000 description 10
210000003556 vascular endothelial cell Anatomy 0.000 description 10
102000043136 MAP kinase family Human genes 0.000 description 9
108091054455 MAP kinase family Proteins 0.000 description 9
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 9
102000003992 Peroxidases Human genes 0.000 description 9
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 9
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 9
238000002725 brachytherapy Methods 0.000 description 9
210000004899 c-terminal region Anatomy 0.000 description 9
238000007912 intraperitoneal administration Methods 0.000 description 9
238000002823 phage display Methods 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
102100035194 Placenta growth factor Human genes 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 8
108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 8
102100038234 Vascular endothelial growth factor D Human genes 0.000 description 8
230000004663 cell proliferation Effects 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
229920000669 heparin Polymers 0.000 description 8
229960002897 heparin Drugs 0.000 description 8
230000003211 malignant effect Effects 0.000 description 8
108040007629 peroxidase activity proteins Proteins 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 7
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 7
206010027476 Metastases Diseases 0.000 description 7
241000699660 Mus musculus Species 0.000 description 7
108091000080 Phosphotransferase Proteins 0.000 description 7
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
101710120037 Toxin CcdB Proteins 0.000 description 7
239000011230 binding agent Substances 0.000 description 7
238000002512 chemotherapy Methods 0.000 description 7
231100000673 dose–response relationship Toxicity 0.000 description 7
238000011580 nude mouse model Methods 0.000 description 7
102000020233 phosphotransferase Human genes 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
238000000159 protein binding assay Methods 0.000 description 7
230000019491 signal transduction Effects 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000758 substrate Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
102000018233 Fibroblast Growth Factor Human genes 0.000 description 6
108050007372 Fibroblast Growth Factor Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
108700020796 Oncogene Proteins 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 6
125000004429 atom Chemical group 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
238000002710 external beam radiation therapy Methods 0.000 description 6
229940126864 fibroblast growth factor Drugs 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
239000006166 lysate Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
230000002297 mitogenic effect Effects 0.000 description 6
230000035772 mutation Effects 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
238000004091 panning Methods 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
230000002285 radioactive effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
206010035226 Plasma cell myeloma Diseases 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
230000035578 autophosphorylation Effects 0.000 description 5
244000309466 calf Species 0.000 description 5
238000001516 cell proliferation assay Methods 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000006957 competitive inhibition Effects 0.000 description 5
239000003636 conditioned culture medium Substances 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000012133 immunoprecipitate Substances 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
210000002510 keratinocyte Anatomy 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000013508 migration Methods 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
230000009871 nonspecific binding Effects 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108050006400 Cyclin Proteins 0.000 description 4
230000004544 DNA amplification Effects 0.000 description 4
206010018338 Glioma Diseases 0.000 description 4
102000009465 Growth Factor Receptors Human genes 0.000 description 4
108010009202 Growth Factor Receptors Proteins 0.000 description 4
229940123011 Growth factor receptor antagonist Drugs 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
206010025323 Lymphomas Diseases 0.000 description 4
102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
108020005038 Terminator Codon Proteins 0.000 description 4
206010064390 Tumour invasion Diseases 0.000 description 4
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
238000011717 athymic nude mouse Methods 0.000 description 4
230000009400 cancer invasion Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
108700010039 chimeric receptor Proteins 0.000 description 4
238000010276 construction Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
108020001756 ligand binding domains Proteins 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
239000008267 milk Substances 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
230000010807 negative regulation of binding Effects 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
108091008598 receptor tyrosine kinases Proteins 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000012679 serum free medium Substances 0.000 description 4
230000011664 signaling Effects 0.000 description 4
210000004988 splenocyte Anatomy 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
238000004448 titration Methods 0.000 description 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
238000005406 washing Methods 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102100034278 Annexin A6 Human genes 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
201000010915 Glioblastoma multiforme Diseases 0.000 description 3
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 3
102100038232 Vascular endothelial growth factor C Human genes 0.000 description 3
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000001621 anti-mitogenic effect Effects 0.000 description 3
230000003305 autocrine Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000000326 densiometry Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000006471 dimerization reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000001976 enzyme digestion Methods 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
230000004927 fusion Effects 0.000 description 3
102000055590 human KDR Human genes 0.000 description 3
102000058223 human VEGFA Human genes 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000003053 immunization Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000002991 immunohistochemical analysis Methods 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000013642 negative control Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
230000003076 paracrine Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
235000020030 perry Nutrition 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
102000027426 receptor tyrosine kinases Human genes 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
230000005740 tumor formation Effects 0.000 description 3
239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
IFPPYSWJNWHOLQ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2Cl)Cl)C(=O)N2C)C2=N1 IFPPYSWJNWHOLQ-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
108090000656 Annexin A6 Proteins 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102100023995 Beta-nerve growth factor Human genes 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
241000724791 Filamentous phage Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
108010093488 His-His-His-His-His-His Proteins 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 2
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108091008606 PDGF receptors Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010054827 Peritoneal lesion Diseases 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010073443 Ribi adjuvant Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
241000011102 Thera Species 0.000 description 2
101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
238000011167 VEGF-binding assay Methods 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000013357 binding ELISA Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
208000025997 central nervous system neoplasm Diseases 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
238000012258 culturing Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000005546 dideoxynucleotide Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000006167 equilibration buffer Substances 0.000 description 2
GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000011404 fractionated radiotherapy Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
201000002222 hemangioblastoma Diseases 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
238000003674 kinase activity assay Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
238000007885 magnetic separation Methods 0.000 description 2
238000013507 mapping Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
150000002902 organometallic compounds Chemical class 0.000 description 2
229960001972 panitumumab Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
150000003246 quinazolines Chemical class 0.000 description 2
230000022910 regulation of vasculogenesis Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
210000002993 trophoblast Anatomy 0.000 description 2
230000005747 tumor angiogenesis Effects 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000008728 vascular permeability Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
RLFXJQPKMZNLMP-UHFFFAOYSA-N 2-phenylprop-2-enenitrile Chemical class N#CC(=C)C1=CC=CC=C1 RLFXJQPKMZNLMP-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical class C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
102000007299 Amphiregulin Human genes 0.000 description 1
108010033760 Amphiregulin Proteins 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
108010037870 Anthranilate Synthase Proteins 0.000 description 1
101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
108010031480 Artificial Receptors Proteins 0.000 description 1
101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000908384 Bos taurus Dipeptidyl peptidase 4 Proteins 0.000 description 1
210000003771 C cell Anatomy 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
101150039808 Egfr gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
108091006020 Fc-tagged proteins Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
208000012766 Growth delay Diseases 0.000 description 1
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
101150088608 Kdr gene Proteins 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000012480 LAL reagent Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
206010024305 Leukaemia monocytic Diseases 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
206010051676 Metastases to peritoneum Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101000932477 Mus musculus Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102400001093 PAK-2p27 Human genes 0.000 description 1
101150012394 PHO5 gene Proteins 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
241000282579 Pan Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
208000012896 Peritoneal disease Diseases 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010082093 Placenta Growth Factor Proteins 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
244000088415 Raphanus sativus Species 0.000 description 1
235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010038934 Retinopathy proliferative Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
208000036822 Small cell carcinoma of the ovary Diseases 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
LXQXZNRPTYVCNG-YPZZEJLDSA-N americium-241 Chemical compound [241Am] LXQXZNRPTYVCNG-YPZZEJLDSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
210000000648 angioblast Anatomy 0.000 description 1
230000006427 angiogenic response Effects 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
238000011122 anti-angiogenic therapy Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000009833 antibody interaction Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
102000025171 antigen binding proteins Human genes 0.000 description 1
108091000831 antigen binding proteins Proteins 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008512 biological response Effects 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000025084 cell cycle arrest Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
150000001854 cinnolines Chemical class 0.000 description 1
229940030792 clinac Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000006341 curative response Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
208000018554 digestive system carcinoma Diseases 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940121647 egfr inhibitor Drugs 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
230000010595 endothelial cell migration Effects 0.000 description 1
230000029578 entry into host Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
108700021358 erbB-1 Genes Proteins 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000045108 human EGFR Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000004201 immune sera Anatomy 0.000 description 1
229940042743 immune sera Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
229940084651 iressa Drugs 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
150000002545 isoxazoles Chemical class 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
229920006008 lipopolysaccharide Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000000504 luminescence detection Methods 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006894 monocytic leukemia Diseases 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002777 nucleoside Chemical class 0.000 description 1
125000003835 nucleoside group Chemical class 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
201000005292 ovarian small cell carcinoma Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
101150040383 pel2 gene Proteins 0.000 description 1
101150050446 pelB gene Proteins 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
108700010839 phage proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
108091005981 phosphorylated proteins Proteins 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
108010017992 platelet-derived growth factor C Proteins 0.000 description 1
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000000649 purine antagonist Substances 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
230000000637 radiosensitizating effect Effects 0.000 description 1
229910052705 radium Inorganic materials 0.000 description 1
HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
229910052704 radon Inorganic materials 0.000 description 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000027240 receptors by ligand Human genes 0.000 description 1
108091008562 receptors by ligand Proteins 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000034932 regulation of DNA biosynthetic process Effects 0.000 description 1
230000006884 regulation of angiogenesis Effects 0.000 description 1
230000031539 regulation of cell division Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
208000013076 thyroid tumor Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
101150108727 trpl gene Proteins 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
238000013042 tunel staining Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
201000011531 vascular cancer Diseases 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
230000004862 vasculogenesis Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ZA200307682A 2001-03-02 2003-10-01 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist. ZA200307682B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/798,689 US6811779B2 (en)	1994-02-10	2001-03-02	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Publications (1)

Publication Number	Publication Date
ZA200307682B true ZA200307682B (en)	2005-01-13

Family

ID=25174032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200307682A ZA200307682B (en)	2001-03-02	2003-10-01	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist.

Country Status (17)

Country	Link
US (1)	US6811779B2 (no)
EP (1)	EP1379276A4 (no)
JP (1)	JP2005506288A (no)
KR (1)	KR20040023590A (no)
BG (1)	BG108214A (no)
BR (1)	BR0207977A (no)
CA (1)	CA2439933A1 (no)
CZ (1)	CZ20032586A3 (no)
EE (1)	EE200300428A (no)
HU (1)	HUP0303378A2 (no)
IL (1)	IL157693A0 (no)
MX (1)	MXPA03007909A (no)
NO (1)	NO20033856L (no)
PL (1)	PL364719A1 (no)
RU (1)	RU2003129228A (no)
WO (1)	WO2002070008A1 (no)
ZA (1)	ZA200307682B (no)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6582959B2 (en) *	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) *	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
US6448077B1 (en) *	1994-02-10	2002-09-10	Imclone Systems, Inc.	Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) *	1994-02-10	2003-06-12	Patricia Rockwell	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
IL117645A (en) *	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
WO1999037751A1 (en) *	1998-01-23	1999-07-29	Imclone Systems Incorporated	Purified populations of stem cells
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en)	1999-01-13	2002-05-23	Bayer Ag	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IT1306704B1 (it) *	1999-05-26	2001-10-02	Sirs Societa Italiana Per La R	Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en) *	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
AU2001259271A1 (en) *	2000-04-28	2001-11-12	Millennium Pharmaceuticals, Inc.	14094, a novel human trypsin family member and uses thereof
KR101135233B1 (ko) *	2000-05-19	2012-04-12	제넨테크, 인크.	ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
AU9598601A (en) *	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
US7041046B2 (en) *	2001-05-07	2006-05-09	Xoft, Inc.	Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia
WO2003000183A2 (en) *	2001-06-20	2003-01-03	Imclone Systems Incorporated	Method of treating atherosclerosis and other inflammatory diseases
US20040241160A1 (en) *	2001-07-13	2004-12-02	Yan Wu	Vegfr-1 antibodies to treat breast cancer
JP2005526482A (ja) *	2001-08-10	2005-09-08	イムクローンシステムズインコーポレイティド	Ｖｅｇｆｒ−１を発現する幹細胞の単離および動員
DK1478358T3 (da)	2002-02-11	2013-10-07	Bayer Healthcare Llc	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068155A2 (en) *	2002-02-12	2003-08-21	Vanderbilt University	Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
CN100457181C (zh) *	2002-03-04	2009-02-04	伊姆克罗尼系统公司	用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
US7498414B2 (en) *	2002-03-04	2009-03-03	Imclone Systems Incorporated	Human antibodies specific to KDR and uses thereof
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20050186204A1 (en) *	2002-06-28	2005-08-25	Peter Carmeliet	Use of antibodies against FLT-1 for the treatment of osteoporosis
US7803372B2 (en) *	2002-10-08	2010-09-28	Immunomedics, Inc.	Antibody therapy
WO2004048525A2 (en) *	2002-11-21	2004-06-10	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1604665B1 (en) *	2003-03-10	2011-05-11	Eisai R&D Management Co., Ltd.	C-kit kinase inhibitor
EP1473043A1 (en) *	2003-04-29	2004-11-03	Boehringer Ingelheim Pharma GmbH & Co.KG	Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE602004011340T2 (de)	2003-05-20	2008-11-06	Bayer Healthcare Llc	Diaryl-harnstoffe mit kinasehemmender wirkung
WO2005001087A2 (en)	2003-06-11	2005-01-06	Regeneron Pharmaceuticals, Inc.	Methods of modifying genes in eukaryotic cells
CL2004001834A1 (es) *	2003-07-23	2005-06-03	Bayer Pharmaceuticals Corp	Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
AU2013200394B2 (en) *	2003-07-23	2015-07-09	Bayer Healthcare Llc	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AR046510A1 (es) *	2003-07-25	2005-12-14	Regeneron Pharma	Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050027196A1 (en) *	2003-07-30	2005-02-03	Fitzgerald Loretta A.	System for processing patient radiation treatment data
CA2534197A1 (en) *	2003-08-06	2005-02-24	Thomas Jefferson University	Use of a vegf antagonist in combination with radiation therapy
US20050196340A1 (en) *	2003-08-06	2005-09-08	Jocelyn Holash	Use of a VEGF antagonist in combination with radiation therapy
JP4303726B2 (ja) *	2003-11-11	2009-07-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウレア誘導体およびその製造方法
WO2005069906A2 (en) *	2004-01-16	2005-08-04	Yale University	Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
PT1735348E (pt) *	2004-03-19	2012-07-24	Imclone Llc	Anticorpo anti-receptor do factor de crescimento humano
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
US20070280944A1 (en) *	2004-04-02	2007-12-06	Adventrx Pharmaceuticals, Inc.	Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
JP2008501651A (ja) *	2004-06-03	2008-01-24	エフ．ホフマン−ラ　ロシュ　アーゲー	イリノテカン（ｃｐｔ−１１）およびｅｇｆｒ阻害剤を用いた処置
EP1797877A4 (en)	2004-09-13	2010-12-15	Eisai Co Ltd	JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) *	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4834553B2 (ja)	2004-09-17	2011-12-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	医薬組成物
DK1819358T3 (da) *	2004-11-18	2014-10-27	Imclone Llc	Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
EP1812064A4 (en) *	2004-11-19	2009-07-08	Cornell Res Foundation Inc	USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY
JP5202956B2 (ja) *	2004-11-19	2013-06-05	コーネルリサーチファンデーションインコーポレーティッド	癌の治療およびモニタリングならびに化学療法薬に関するスクリーニングにおける血管内皮増殖因子受容体１＋細胞の使用法
WO2006078746A2 (en) *	2005-01-19	2006-07-27	Mathew Mark Zuckerman	Method, compositions and classification for tumor diagnostics and treatment
CA2592177A1 (en)	2005-01-21	2006-07-27	Genentech, Inc.	Fixed dosing of her antibodies
BRPI0606542A8 (pt) *	2005-02-23	2018-03-20	Genentech Inc	métodos para aumentar o tempo de progressão de uma doença (ttp)
TW200642695A (en) *	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080219977A1 (en) *	2005-07-27	2008-09-11	Isaiah Josh Fidler	Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US20100105031A1 (en) *	2005-08-01	2010-04-29	Esai R & D Management Co., Ltd.	Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en)	2005-08-02	2015-04-14	Eisai R&D Management Co., Ltd.	Method for assay on the effect of vascularization inhibitor
US20090053236A1 (en) *	2005-11-07	2009-02-26	Eisai R & D Management Co., Ltd.	USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
CN102512281A (zh) *	2005-11-15	2012-06-27	内奥维斯塔公司	用于眼内近距离治疗的方法和器具
WO2007061127A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
CN101443009A (zh)	2006-05-18	2009-05-27	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
US20090203693A1 (en) *	2006-06-29	2009-08-13	Eisai R & D Management Co., Ltd.	Therapeutic agent for liver fibrosis
US8865737B2 (en) *	2006-08-28	2014-10-21	Eisai R&D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) *	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
KR20150039212A (ko)	2007-03-02	2015-04-09	제넨테크, 인크.	낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
BRPI0810374A2 (pt) *	2007-04-17	2014-10-29	Imclone Llc	Inibidores específicos do pdgfrbeta
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (es) *	2007-06-08	2016-09-20	Genentech, Inc.	Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
KR100883430B1 (ko) *	2007-06-13	2009-02-12	한국생명공학연구원	혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
PT2170956E (pt) *	2007-06-15	2015-02-05	Medigene Ag	Tratamento de tumores utilizando um anticorpo anti-l1 específico
WO2009060945A1 (ja)	2007-11-09	2009-05-14	Eisai R & D Management Co., Ltd.	血管新生阻害物質と抗腫瘍性白金錯体との併用
MX2010008187A (es) *	2008-01-29	2010-08-10	Eisai R&D Man Co Ltd	Uso combinado de inhibidor de angiogenesis y taxano.
PT2242773T (pt)	2008-02-11	2017-09-15	Cure Tech Ltd	Anticorpos monoclonais para o tratamento de tumores
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
EP2393513B1 (en)	2009-02-06	2016-10-19	The General Hospital Corporation	Methods of treating vascular lesions
TW201544123A (zh)	2009-03-20	2015-12-01	Genentech Inc	抗-ｈｅｒ抗體
US8663210B2 (en)	2009-05-13	2014-03-04	Novian Health, Inc.	Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
EP2435071A1 (en)	2009-05-29	2012-04-04	F. Hoffmann-La Roche AG	Modulators for her2 signaling in her2 expressing patients with gastric cancer
WO2011028642A1 (en)	2009-09-04	2011-03-10	University Of Louisville Research Foundation, Inc.	Genetic determinants of prostate cancer risk
CN102892779B (zh)	2010-02-18	2016-12-21	基因泰克公司	神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
CA2802644C (en)	2010-06-25	2017-02-21	Eisai R & D Management Co., Ltd.	Antitumor agent using compounds having kinase inhibitory effect in combination
EP2643353A1 (en)	2010-11-24	2013-10-02	Novartis AG	Multispecific molecules
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112013021941B1 (pt)	2011-04-18	2022-11-16	Eisai R & D Management Co., Ltd	Agente terapêutico para tumor
JO3283B1 (ar)	2011-04-26	2018-09-16	Sanofi Sa	تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2841809T3 (es)	2011-06-03	2021-07-09	Eisai R&D Man Co Ltd	Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
BR112014003431A2 (pt)	2011-08-17	2017-06-13	Genentech Inc	anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
US9327023B2 (en)	2011-10-25	2016-05-03	The Regents Of The University Of Michigan	HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
JP2015500638A (ja)	2011-11-30	2015-01-08	ジェネンテック，インコーポレイテッド	癌におけるｅｒｂｂ３変異
EP2788500A1 (en)	2011-12-09	2014-10-15	F.Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
AU2013240261A1 (en)	2012-03-27	2014-09-18	Genentech, Inc.	Diagnosis and treatments relating to HER3 inhibitors
WO2014083178A1 (en)	2012-11-30	2014-06-05	F. Hoffmann-La Roche Ag	Identification of patients in need of pd-l1 inhibitor cotherapy
EP2937337A4 (en)	2012-12-21	2016-06-22	Eisai R&D Man Co Ltd	AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA2930987A1 (en)	2013-01-11	2014-07-17	Massachusetts Eye And Ear Infirmary	Cyp450 lipid metabolites reduce inflammation and angiogenesis
MX368099B (es)	2013-05-14	2019-09-19	Eisai R&D Man Co Ltd	Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
TW201622744A (zh) *	2014-03-04	2016-07-01	美國禮來大藥廠	癌症之組合療法
PT3170005T (pt)	2014-07-18	2019-07-16	Sanofi Sa	Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
SI3524595T1 (sl)	2014-08-28	2022-10-28	Eisai R&D Management Co., Ltd.	Derivat kinolina visoke čistosti in postopek njegove proizvodnje
US20180028662A1 (en)	2015-02-25	2018-02-01	Eisai R&D Management Co., Ltd.	Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en)	2015-03-04	2016-09-09	Merck Sharpe & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
JP6542383B2 (ja) *	2015-04-14	2019-07-10	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	抗血管新生及び標的がん療法のための抗ｖｅｇｆｒ２ヒト抗体
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
KR102587702B1 (ko)	2015-08-20	2023-10-12	에자이 알앤드디 매니지먼트 가부시키가이샤	종양 치료제
EP3454863A1 (en)	2016-05-10	2019-03-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
CN106892980B (zh) *	2017-01-25	2020-08-04	长春金赛药业有限责任公司	抗vegfr2单克隆抗体及其应用
JP6581320B2 (ja)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
MX2019013014A (es)	2017-05-16	2020-08-06	Eisai R&D Man Co Ltd	Tratamiento de carcinoma hepatocelular.
EP3656791A4 (en) *	2017-07-18	2021-03-31	Kyowa Kirin Co., Ltd.	Anti-human ccr1 monoclonal antibody
JP2022521353A (ja)	2019-03-22	2022-04-06	リフレクションファーマシューティカルズ，インコーポレイテッド	Ｖｅｇｆのためのｄ－ペプチド性化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US301299A (en)		1884-07-01		Vehicle-spring
US2132498A (en)	1936-07-22	1938-10-11	Smith	Roller bit
KR870008714A (ko)	1986-03-07	1987-10-20	사까이 유미	도광섬유 조명장치
US5194596A (en)	1989-07-27	1993-03-16	California Biotechnology Inc.	Production of vascular endothelial cell growth factor
DE4003229A1 (de)	1990-02-03	1991-08-08	Bosch Gmbh Robert	Elektromagnetisch betaetigbares ventil
CA2083401C (en)	1991-02-22	2003-03-25	Bruce I. Terman	Identification of a novel human receptor tyrosine kinase gene
US5185438A (en) *	1991-04-02	1993-02-09	The Trustees Of Princeton University	Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5367057A (en) *	1991-04-02	1994-11-22	The Trustees Of Princeton University	Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en) *	1991-04-02	1993-12-14	The Trustees Of Princeton University	Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
AU3236793A (en)	1991-12-12	1993-07-19	Berlex Laboratories, Inc.	Recombinant and chimeric antibodies to c-erbB-2
US5861301A (en)	1992-02-20	1999-01-19	American Cayanamid Company	Recombinant kinase insert domain containing receptor and gene encoding same
WO1993021319A1 (en)	1992-04-08	1993-10-28	Cetus Oncology Corporation	HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CA2085291A1 (en)	1992-07-30	1994-01-31	Martin L. Breitman	Novel receptor tyrosine kinase
DE69233803D1 (de)	1992-10-28	2011-03-31	Genentech Inc	Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US5677181A (en)	1992-10-29	1997-10-14	The Australian National University	Angiogenesis inhibitory antibodies
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CN1173991C (zh)	1992-11-13	2004-11-03	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k-1
US5981569A (en)	1992-11-13	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5712395A (en)	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH07131958A (ja)	1993-11-04	1995-05-19	Odawara Eng:Kk	ステータ巻線機
US5840301A (en)	1994-02-10	1998-11-24	Imclone Systems Incorporated	Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
AUPM379394A0 (en)	1994-02-10	1994-03-03	Ludwig Institute For Cancer Research	Immunointeractive molecules - i
US5861499A (en) *	1994-02-10	1999-01-19	Imclone Systems Incorporated	Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
EP0817775B1 (en)	1995-03-30	2001-09-12	Pfizer Inc.	Quinazoline derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
EP0831880A4 (en) *	1995-06-07	2004-12-01	Imclone Systems Inc	ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
EP0888349B1 (en)	1996-01-23	2002-05-22	Novartis AG	Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
DE69734513T2 (de)	1996-06-24	2006-07-27	Pfizer Inc.	Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
DE69736222T2 (de)	1996-11-21	2007-05-24	Kyowa Hakko Kogyo K.K.	Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
DE69839338T2 (de)	1997-02-05	2008-07-10	Warner-Lambert Company Llc	Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
CA2328893A1 (en)	1998-05-20	1999-11-25	Kyowa Hakko Kogyo Co., Ltd.	Vegf activity inhibitors
AU763669B2 (en)	1998-09-29	2003-07-31	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9824579D0 (en) *	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
EA003786B1 (ru)	1998-11-19	2003-10-30	Варнер Ламберт Компани	N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US6297238B1 (en) *	1999-04-06	2001-10-02	Basf Aktiengesellschaft	Therapeutic agents

2001
- 2001-03-02 US US09/798,689 patent/US6811779B2/en not_active Expired - Fee Related
2002
- 2002-03-04 IL IL15769302A patent/IL157693A0/xx unknown
- 2002-03-04 EE EEP200300428A patent/EE200300428A/xx unknown
- 2002-03-04 EP EP02717550A patent/EP1379276A4/en not_active Ceased
- 2002-03-04 CA CA002439933A patent/CA2439933A1/en not_active Abandoned
- 2002-03-04 BR BR0207977-1A patent/BR0207977A/pt not_active Application Discontinuation
- 2002-03-04 WO PCT/US2002/006762 patent/WO2002070008A1/en not_active Application Discontinuation
- 2002-03-04 RU RU2003129228/14A patent/RU2003129228A/ru not_active Application Discontinuation
- 2002-03-04 HU HU0303378A patent/HUP0303378A2/hu unknown
- 2002-03-04 KR KR10-2003-7011532A patent/KR20040023590A/ko not_active Withdrawn
- 2002-03-04 PL PL02364719A patent/PL364719A1/xx unknown
- 2002-03-04 MX MXPA03007909A patent/MXPA03007909A/es unknown
- 2002-03-04 CZ CZ20032586A patent/CZ20032586A3/cs unknown
- 2002-03-04 JP JP2002569180A patent/JP2005506288A/ja active Pending
2003
- 2003-09-01 NO NO20033856A patent/NO20033856L/no not_active Application Discontinuation
- 2003-09-30 BG BG108214A patent/BG108214A/xx unknown
- 2003-10-01 ZA ZA200307682A patent/ZA200307682B/en unknown

Also Published As

Publication number	Publication date
MXPA03007909A (es)	2005-06-03
EP1379276A4 (en)	2004-06-30
EE200300428A (et)	2004-10-15
KR20040023590A (ko)	2004-03-18
PL364719A1 (en)	2004-12-13
CA2439933A1 (en)	2002-09-12
HUP0303378A2 (hu)	2003-12-29
RU2003129228A (ru)	2005-03-10
NO20033856D0 (no)	2003-09-01
BG108214A (en)	2004-09-30
IL157693A0 (en)	2004-03-28
WO2002070008A1 (en)	2002-09-12
BR0207977A (pt)	2005-02-01
CZ20032586A3 (cs)	2004-08-18
US20030103973A1 (en)	2003-06-05
JP2005506288A (ja)	2005-03-03
US6811779B2 (en)	2004-11-02
EP1379276A1 (en)	2004-01-14
NO20033856L (no)	2003-11-03

Publication	Publication Date	Title
US20090022716A1 (en)	2009-01-22	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en)	2004-11-02	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
EP2158217B1 (en)	2014-01-15	Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
US6365157B2 (en)	2002-04-02	Monoclonal antibodies specific to VEGF receptors and uses thereof
US6448077B1 (en)	2002-09-10	Chimeric and humanized monoclonal antibodies specific to VEGF receptors
EP1735348B1 (en)	2012-06-20	Human anti-epidermal growth factor receptor antibody
CN100457181C (zh)	2009-02-04	用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
AU2002248544A1 (en)	2002-09-19	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
CN102133403A (zh)	2011-07-27	用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法
HK1118229A1 (en)	2009-02-06	Human antibodies specific to kdr and uses thereof
HK1118229B (en)	2011-09-23	Human antibodies specific to kdr and uses thereof